Science News
from research organizations

Experimental treatment protects monkeys from lethal Ebola virus post-exposure

Date:
May 29, 2010
Source:
US Army Medical Research Institute of Infectious Diseases
Summary:
Scientists using tiny particles of genetic material to interfere in the replication process of the deadly Ebola virus have successfully prevented monkeys exposed to that virus from dying of hemorrhagic fever. The proof-of-concept study suggests that such protection also should be possible in humans.
Share:
         
Total shares:  
FULL STORY

Scientists using tiny particles of genetic material to interfere in the replication process of the deadly Ebola virus have successfully prevented monkeys exposed to that virus from dying of hemorrhagic fever. The proof-of-concept study, published in this week's issue of The Lancet, suggests that such protection also should be possible in humans.

"Over the past decade, we have evaluated numerous therapeutic approaches for the treatment of lethal viruses, such as Ebola," said co-author Dr. Lisa E. Hensley of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). "None of them have conferred complete protection to Ebola virus-infected primates -- until now."

Using particles called small interfering RNAs (siRNAs), the authors targeted a protein (called the L protein) that is essential for Ebola virus replication. RNA inhibitors, as they are commonly called, are based on a natural gene silencing mechanism used by all cells, and RNAi therapeutics rely on a delivery technology to be effective.

Lipid nanoparticles (LNPs) are the most widely used siRNA delivery approaches. In this study, the research team used a proprietary technology called SNALP, or stable nucleic acid-lipid particles, to deliver the therapeutics to disease sites in animal models infected with the Zaire strain of Ebola virus (ZEBOV).

A group of three rhesus macaques was given anti-ZEBOV siRNAs intravenously, 30 minutes after exposure to the virus, and again on days 1, 3, and 5. A second group of four macaques was given the treatment after 30 minutes, and on days 1, 2, 3, 4, 5, and 6, after challenge with ZEBOV.

Two of the three animals in the first group (which received four post-exposure treatments) were protected from lethal ZEBOV infection and survived. All four of the monkeys given seven post-exposure treatments were protected. The treatment regimen in the second study was well tolerated, with minor changes in liver enzymes that might have been related to viral infection.

The study represents the first demonstration of complete protection against a lethal human infectious disease in nonhuman primates using RNAi, according to lead author Dr. Thomas W. Geisbert of the Boston University School of Medicine.

"We believe this work justifies the immediate development of Ebola SNALP as a countermeasure to treat Ebola infected patients, either in outbreaks or accidental laboratory exposures," he said.

Ebola virus causes hemorrhagic fever with case fatality rates as high as 80 percent in humans. The virus, which is infectious by aerosol (although more commonly spread through blood and bodily fluids of infected patients), is of concern both as a global health threat and a potential agent of biological warfare or terrorism.

Currently there are no available vaccines or therapies, so researchers working with Ebola virus must do so in maximum containment (Biosafety Level 4) laboratories. In these specially designed laboratories, investigators wear positive pressure "space suits" and breathe filtered air as they work, and all laboratory waste streams are sterilized.

The SNALP-RNAi therapeutic used in the study was developed by Tekmira Pharmaceuticals Corporation of Vancouver, BC. Previous research showed that these siRNAs completely protected guinea pigs when administered shortly after a lethal dose of ZEBOV was administered. While rodent studies are useful for screening prospective medical countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models.

Further studies in monkeys would be necessary to refine dosing, toxicology and other issued before the treatment could be licensed for human use.

"The significance of this report goes beyond the protection against Ebola virus," said COL John P. Skvorak, commander of USAMRIID. "It also represents the potential for this concept to be applied to other viral infections."

The study was a collaborative effort between USAMRIID, Boston University and Tekmira, and was partly funded by the Defense Threat Reduction Agency's Transformational Medical Technologies Initiative.


Story Source:

The above story is based on materials provided by US Army Medical Research Institute of Infectious Diseases. Note: Materials may be edited for content and length.


Journal Reference:

  1. Thomas W. Geisbert, Amy C. H. Lee, Marjorie Robbins, Joan B. Geisbert, Anna N. Honko, Vandana Sood, Joshua C. Johnson, Susan de Jong, Iran Tavakoli, Adam Judge, Lisa E. Hensley, Ian MacLachlan. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. The Lancet, 29 May 2010; 375: 1896-190 DOI: 10.1016/S0140-6736(10)60357-1

Cite This Page:

US Army Medical Research Institute of Infectious Diseases. "Experimental treatment protects monkeys from lethal Ebola virus post-exposure." ScienceDaily. ScienceDaily, 29 May 2010. <www.sciencedaily.com/releases/2010/05/100528081436.htm>.
US Army Medical Research Institute of Infectious Diseases. (2010, May 29). Experimental treatment protects monkeys from lethal Ebola virus post-exposure. ScienceDaily. Retrieved April 27, 2015 from www.sciencedaily.com/releases/2010/05/100528081436.htm
US Army Medical Research Institute of Infectious Diseases. "Experimental treatment protects monkeys from lethal Ebola virus post-exposure." ScienceDaily. www.sciencedaily.com/releases/2010/05/100528081436.htm (accessed April 27, 2015).

Share This Page:


Health & Medicine News
April 27, 2015

Latest Headlines
updated 12:56 pm ET